Bradley Duffy

Array ( [id] => 9888538 [patent_doc_number] => 08974787 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-03-10 [patent_title] => 'Antagonistic human light-specific human monoclonal antibodies' [patent_app_type] => utility [patent_app_number] => 13/889608 [patent_app_country] => US [patent_app_date] => 2013-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 41 [patent_no_of_words] => 69149 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 162 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13889608 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9093725 [patent_doc_number] => 20130273036 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-17 [patent_title] => 'Fn14 Binding Proteins and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 13/851153 [patent_app_country] => US [patent_app_date] => 2013-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 78 [patent_figures_cnt] => 78 [patent_no_of_words] => 65572 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13851153 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9345220 [patent_doc_number] => 08664367 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-03-04 [patent_title] => 'IL-I binding proteins' [patent_app_type] => utility [patent_app_number] => 13/847862 [patent_app_country] => US [patent_app_date] => 2013-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 92037 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13847862 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10233251 [patent_doc_number] => 20150118245 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-30 [patent_title] => 'Predictive Biomarkers for CTLA-4 Blockade Therapy and for PD-1 Blockade Therapy' [patent_app_type] => utility [patent_app_number] => 14/399669 [patent_app_country] => US [patent_app_date] => 2013-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 28192 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14399669 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9181252 [patent_doc_number] => 20130323237 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-12-05 [patent_title] => 'ORGANIC COMPOUNDS' [patent_app_type] => utility [patent_app_number] => 13/838833 [patent_app_country] => US [patent_app_date] => 2013-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 33064 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13838833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10628742 [patent_doc_number] => 09346887 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-24 [patent_title] => 'CD37-binding molecules and immunoconjugates thereof' [patent_app_type] => utility [patent_app_number] => 13/796768 [patent_app_country] => US [patent_app_date] => 2013-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 44787 [patent_no_of_claims] => 41 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13796768 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9858346 [patent_doc_number] => 20150038363 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-02-05 [patent_title] => 'Method for Stimulating T Cell and Use Thereof' [patent_app_type] => utility [patent_app_number] => 14/383391 [patent_app_country] => US [patent_app_date] => 2013-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 10862 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14383391 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8976604 [patent_doc_number] => 20130210034 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-15 [patent_title] => 'COMPLEX PHOSPHOPROTEIN ACTIVATION PROFILES' [patent_app_type] => utility [patent_app_number] => 13/781312 [patent_app_country] => US [patent_app_date] => 2013-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 34762 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13781312 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8865536 [patent_doc_number] => 20130149238 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-13 [patent_title] => 'Anti-VEGF Antibody Compositions and Methods' [patent_app_type] => utility [patent_app_number] => 13/768005 [patent_app_country] => US [patent_app_date] => 2013-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 93326 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13768005 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9174417 [patent_doc_number] => 20130316402 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-28 [patent_title] => 'ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR' [patent_app_type] => utility [patent_app_number] => 13/766150 [patent_app_country] => US [patent_app_date] => 2013-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 45 [patent_no_of_words] => 74340 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13766150 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8892456 [patent_doc_number] => 20130165640 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-27 [patent_title] => 'ACCEPTOR FRAMEWORK FOR CDR GRAFTING' [patent_app_type] => utility [patent_app_number] => 13/765326 [patent_app_country] => US [patent_app_date] => 2013-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 10334 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13765326 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8892455 [patent_doc_number] => 20130165639 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-27 [patent_title] => 'ACCEPTOR FRAMEWORK FOR CDR GRAFTING' [patent_app_type] => utility [patent_app_number] => 13/765302 [patent_app_country] => US [patent_app_date] => 2013-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 10333 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13765302 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9041617 [patent_doc_number] => 20130244256 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-09-19 [patent_title] => 'Compositions and Methods for Treating and Diagnosing Cancer' [patent_app_type] => utility [patent_app_number] => 13/762645 [patent_app_country] => US [patent_app_date] => 2013-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 64362 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13762645 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9844474 [patent_doc_number] => 08946390 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-02-03 [patent_title] => 'Cancer-associated antigen' [patent_app_type] => utility [patent_app_number] => 13/750849 [patent_app_country] => US [patent_app_date] => 2013-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 21 [patent_no_of_words] => 25260 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13750849 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10560718 [patent_doc_number] => 09284379 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-15 [patent_title] => 'FGFR4 antibodies' [patent_app_type] => utility [patent_app_number] => 13/744631 [patent_app_country] => US [patent_app_date] => 2013-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 11962 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13744631 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9093739 [patent_doc_number] => 20130273050 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-17 [patent_title] => 'PHARMACEUTICAL COMPOSITIONS WITH RESISTANCE TO SOLUBLE CEA' [patent_app_type] => utility [patent_app_number] => 13/740358 [patent_app_country] => US [patent_app_date] => 2013-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 31215 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13740358 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8939465 [patent_doc_number] => 20130189263 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-07-25 [patent_title] => 'ANTIGEN-BINDING MOLECULE AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/727059 [patent_app_country] => US [patent_app_date] => 2012-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 13524 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13727059 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8767084 [patent_doc_number] => 20130095120 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-04-18 [patent_title] => 'ANTI-PLATELET MEMBRANE GLYCOPROTEIN VI MONOCLONAL ANTIBODY' [patent_app_type] => utility [patent_app_number] => 13/721547 [patent_app_country] => US [patent_app_date] => 2012-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 47 [patent_no_of_words] => 47032 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13721547 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10628741 [patent_doc_number] => 09346886 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-24 [patent_title] => 'Humanized anti-CDCP1 antibodies' [patent_app_type] => utility [patent_app_number] => 13/721553 [patent_app_country] => US [patent_app_date] => 2012-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 12264 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13721553 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9401178 [patent_doc_number] => 08691228 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-04-08 [patent_title] => 'Stable and soluble antibodies inhibiting TNFα' [patent_app_type] => utility [patent_app_number] => 13/708500 [patent_app_country] => US [patent_app_date] => 2012-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 11 [patent_no_of_words] => 17671 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13708500 [rel_patent_id] =>[rel_patent_doc_number] =>)